A number of other research analysts have also weighed in on CHE. Bank of America boosted their target price on shares of Chemed from $470.00 to $500.00 and gave the stock a buy rating in a research report on Friday, September 6th. Oppenheimer boosted their target price on shares of Chemed from $400.00 to $430.00 and gave the stock an outperform rating in a research report on Thursday, August 1st. Finally, Royal Bank of Canada boosted their target price on shares of Chemed to $405.00 and gave the stock a sector perform rating in a research report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. Chemed presently has an average rating of Hold and a consensus target price of $411.25.
Chemed stock traded down $1.91 on Wednesday, reaching $412.47. 57,339 shares of the stock were exchanged, compared to its average volume of 124,742. The stock has a market cap of $6.57 billion, a PE ratio of 34.57, a PEG ratio of 2.80 and a beta of 1.11. The company has a current ratio of 0.81, a quick ratio of 0.78 and a debt-to-equity ratio of 0.25. Chemed has a twelve month low of $260.03 and a twelve month high of $441.79. The firm has a fifty day moving average price of $425.22 and a two-hundred day moving average price of $368.67.
In other news, VP Michael D. Witzeman sold 4,349 shares of the business’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $432.50, for a total transaction of $1,880,942.50. Following the transaction, the vice president now owns 5,175 shares in the company, valued at approximately $2,238,187.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Donald E. Saunders sold 400 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $432.87, for a total transaction of $173,148.00. Following the transaction, the director now owns 7,408 shares in the company, valued at approximately $3,206,700.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,812 shares of company stock valued at $20,005,507. Company insiders own 3.96% of the company’s stock.
Several large investors have recently bought and sold shares of CHE. Krane Funds Advisors LLC bought a new position in shares of Chemed during the 2nd quarter worth about $26,000. Advisory Services Network LLC increased its holdings in shares of Chemed by 117.9% during the 2nd quarter. Advisory Services Network LLC now owns 85 shares of the company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Harvest Fund Management Co. Ltd increased its holdings in shares of Chemed by 152.9% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 177 shares of the company’s stock worth $64,000 after purchasing an additional 107 shares during the period. Steward Partners Investment Advisory LLC bought a new position in shares of Chemed during the 2nd quarter worth about $92,000. Finally, Panagora Asset Management Inc. increased its holdings in shares of Chemed by 613.7% during the 2nd quarter. Panagora Asset Management Inc. now owns 364 shares of the company’s stock worth $131,000 after purchasing an additional 313 shares during the period. Institutional investors own 87.12% of the company’s stock.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Further Reading: What is a short straddle?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.